The interesting thing about this study is that we asked each patient to do a fecal test and only 52% did (people don’t like poop) That test performed as expected with a sens of 67% and spec of 96%. In head to head, Freenome achieved 100% sens and 96% spec.
-
-
Prikaži ovu nitHvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
-
-
Performance didn’t increase with stage?
-
16/17 (94%) early stage, 10/11 (91%) late stage.
- Još 4 druga odgovora
Novi razgovor -
-
-
theres is some evidence that blood based tests just simply won't ever work as well as colorguard for EARLY cancer
-
Rather than speculating, we will see soon enough if those assumptions are actually true!
Kraj razgovora
Novi razgovor -
-
-
Will your study be done early enough to be included in the next USPSTF guidelines? If not, the first time a blood-based test would potentially be in the USPSTF guidelines would be in the 2026 to 2027 timeframe.
-
We shall see if those assumptions are true or not :)
Kraj razgovora
Novi razgovor -
-
-
Can you also detect advanced precancerous lesions? Sensitivity for CRC seems same ballpark as
$EXAS test - do you concur? -
Cologuard is 92% Sens and 87% Spec. We will share precancerous adenoma data later!
- Još 1 odgovor
Novi razgovor -
-
-
Congratulations! Incredible results.
Hvala. Twitter će to iskoristiti za poboljšanje vaše vremenske crte. PoništiPoništi
-
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.